ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma Published: Oct 29, 2021 | Tags: ADC, EMA, MAA, Zynlonta, R/R Diffuse Large B-Cell Lymphoma […]readmore
Tags : Immunic
Shots: The company has completed the enrolment in the P-II CALDOSE-1 trial to evaluate the efficacy & safety of IMU-838 (10/30/45mg, PO) vs PBO in 263 patients with mod. to […]readmore
Everest’s SPR206 Receives the NMPA’s IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections Published: Sept 24, 2021 | Tags: Everest, SPR206, NMPA, IND, Approval, MDR Gram-Negative Bacterial Infections […]readmore
Shots: The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza The preclinical research showed that IMU-838 strongly […]readmore
Lysogene Receives the US FDA’s Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis Published: July 9, 2021 | Tags: Lysogene, US, FDA, Fast Track Designation, LYS-GM101 Gene […]readmore
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it Life sciences companies are putting all of their efforts […]readmore
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected […]readmore
Shots: The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries, 209 patients received at least one dose of IMU-838 vs […]readmore
Shots: Immunic has exercised its exclusive option to license a group of compounds for Daiichi’s IMU-856. Daiichi to receive up front, certain future development, approval & sales milestone payments plus […]readmore